TRex Bio, Inc. (TRXB) – What Are Investment Firms Thinking About This Stock?

Shares of TRex Bio, Inc. (NASDAQ:TRXB) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $29.67.

TRXB has been the topic of a number of research reports. Cantor Fitzgerald assumed coverage on shares of TRex Bio in a research report on Tuesday. They set an “overweight” rating on the stock. Evercore started coverage on TRex Bio in a research note on Tuesday. They issued a “strong-buy” rating on the stock. Wedbush initiated coverage on TRex Bio in a report on Monday. They set an “outperform” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. started coverage on TRex Bio in a research report on Tuesday. They set an “overweight” rating and a $20.00 target price for the company. Finally, Zacks Research assumed coverage on TRex Bio in a report on Tuesday. They issued a “hold” rating for the company.

Insider Transactions at TRex Bio

In related news, major shareholder Alexandria Venture Investments bought 178,571 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were bought at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the purchase, the insider directly owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TRex Bio Trading Down 1.3%

NASDAQ:TRXB opened at $13.55 on Thursday. TRex Bio has a fifty-two week low of $12.50 and a fifty-two week high of $16.56.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.